Amneal (AMRX) Co-CEO gains shares via RSU and performance awards
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Amneal Pharmaceuticals, Inc. President & Co-CEO Chirag K. Patel reported multiple equity award vestings and related share movements. On March 3, 2026, performance-based restricted stock units covering 733,944 units vested after achieving a performance threshold that resulted in vesting of 200% of the targeted number, and were settled into the same number of Class A Common shares on a one-for-one basis. Additional restricted stock units covering 59,931 units also converted into Class A Common Stock.
To cover tax withholding obligations from these vestings, the reporting person disposed of 297,537 and 15,616 Class A shares at per-share prices of $13.31, and on March 4, 2026 disposed of a further 37,825 Class A shares at $13.30, all characterized as share withholding rather than open-market sales. After these transactions, direct holdings reported include 1,393,470 shares of Class A Common Stock and 185,185 restricted stock units, with an additional 21,269,420 Class A shares held indirectly through family trusts.
Positive
- None.
Negative
- None.
Insider Trade Summary
886,468 shares exercised/converted
Mixed
10 txns
Insider
Patel Chirag K.
Role
President & Co-CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 92,593 | $0.00 | -- |
| Exercise | Class A Common Stock | 92,593 | $0.00 | -- |
| Tax Withholding | Class A Common Stock | 37,825 | $13.30 | $503K |
| Exercise | Restricted Stock Units | 59,931 | $0.00 | -- |
| Exercise | Performance-Based Restricted Stock Units | 733,944 | $0.00 | -- |
| Exercise | Class A Common Stock | 59,931 | $0.00 | -- |
| Tax Withholding | Class A Common Stock | 15,616 | $13.31 | $208K |
| Exercise | Class A Common Stock | 733,944 | $0.00 | -- |
| Tax Withholding | Class A Common Stock | 297,537 | $13.31 | $3.96M |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 185,185 shares (Direct);
Class A Common Stock — 1,431,295 shares (Direct);
Performance-Based Restricted Stock Units — 0 shares (Direct);
Class A Common Stock — 21,269,420 shares (Indirect, By Family Trusts)
Footnotes (1)
- Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units. On March 3, 2025, the Reporting Person was granted 239,726 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. On March 4, 2024, the reporting person was granted 370,370 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
FAQ
What insider transactions did AMRX President & Co-CEO Chirag Patel report?
Chirag K. Patel reported RSU and performance-based RSU vestings converting into Class A Common Stock, plus related share withholding to cover taxes. These movements changed his reported direct and indirect ownership positions in Amneal’s Class A shares and restricted stock units.
How many performance-based RSUs vested for AMRX’s Co-CEO in March 2026?
Performance-based restricted stock units covering 733,944 units were certified as meeting the performance threshold and vested on March 3, 2026. They reflected 200% of the targeted number and were settled into an equal number of Amneal Class A Common shares on a one-for-one basis.
What are Chirag Patel’s reported direct holdings of AMRX Class A stock after these transactions?
Following the March 3–4, 2026 transactions, Chirag K. Patel reported direct ownership of 1,393,470 shares of Amneal Class A Common Stock. He also reported 185,185 restricted stock units as directly held awards that represent contingent rights to receive additional Class A shares.
What new RSU grants to AMRX’s Co-CEO are disclosed in the footnotes?
Footnotes state that on March 3, 2025, Chirag K. Patel was granted 239,726 restricted stock units, vesting in four equal installments from the first anniversary. On March 4, 2024, he was granted 370,370 restricted stock units with the same four-installment vesting structure.